oseltamivir acid (TargetMol)
Structured Review

Oseltamivir Acid, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir/pmc13198263-265-16-24
Average 97 stars, based on 5 article reviews
Images
1) Product Images from "A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1"
Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
Journal: Acta Pharmaceutica Sinica. B
doi: 10.1016/j.apsb.2026.02.003
Figure Legend Snippet: The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or oseltamivir phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).
Techniques Used: Infection, Analysis, Isolation, Virus, Real-time Polymerase Chain Reaction, Western Blot, Quantitative Proteomics, Staining, H&E Stain
Figure Legend Snippet: Compound H1N1-17 showed synergistic effect with oseltamivir acid against H1N1. (A) The three-dimensional (3-D) dose-response surface of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid. The dose-response surface exhibited a convex shape resembling a flipping sail, especially at an inhibition level of 40%–60% (green). According to the principle of Loewe additivity, the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid was synergistic. (B) The two-dimensional isobologram of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid at the inhibition effect of 50%. By controlling the concentrations of compound H1N1-17 and oseltamivir acid as a constant separately, the EC 50 against H1N1 of another compound could be calculated to obtain a series of data points, and then the cross-sectional curve in the 3-D dose-response surface at the inhibition level of 50% was obtained, which presented a concave upward curve. According to the principle of Loewe additivity, compound H1N1-17 showed a synergistic effect with oseltamivir acid against H1N1.
Techniques Used: Inhibition
Figure Legend Snippet: Combination index (CI) of compound H1N1-17 and oseltamivir acid at 50% inhibition.
Techniques Used: Inhibition
Related Articles
Infection:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: Analysis:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: Isolation:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: Virus:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: Real-time Polymerase Chain Reaction:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: Western Blot:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: Quantitative Proteomics:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: Staining:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: H&E Stain:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: Inhibition:Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1 Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Article Snippet: |